

```

chain nodes :
  7  8  9 10 11 12 13 14 17 18 19 20 21 22 23 24 25 26 41 42
ring nodes :
  1  2  3  4  5  6
chain bonds :
  1-9 4-8 5-41 7-10 7-12 7-14 8-10 10-11 12-13 14-17 19-20 21-22 22-25 23-24 23-26
  41-42
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
  1-2 1-6 1-9 2-3 3-4 4-5 5-6 5-41 7-10 7-12 10-11 12-13 14-17 23-26 41-42
exact bonds :
  4-8 7-14 8-10 19-20 21-22 22-25 23-24

```

G1:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS
 12:Atom 13:Atom 14:CLASS 17:Atom 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
 24:CLASS 25:CLASS 26:CLASS 41:CLASS 42:Atom

Generic attributes :
 18:
 Saturation : Saturated
 Number of Carbon Atoms : less than 7
 42:
 Saturation : Unsaturated

Element Count :
 Node 18: Limited
 C,C1-5

=>

Uploading C:\Program Files\Stnexp\Queries\10510467.str



```

chain nodes :
7  8  9 10 11 12 13 14 17 18 19 20 21 22 23 24 25 26 41 42
ring nodes :
1  2  3  4  5  6
chain bonds :
1-9  4-8  5-41  7-10  7-12  7-14  8-10  10-11  12-13  14-17  19-20  21-22  22-25
23-24  23-26  41-42
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  1-9  2-3  3-4  4-5  5-6  5-41  7-10  7-12  10-11  12-13  14-17  23-26
41-42

```

exact bonds :
 4-8 7-14 8-10 19-20 21-22 22-25 23-24

G1:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:CLASS 17:Atom 18:CLASS 19:CLASS 20:CLASS
 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 41:CLASS 42:Atom

Generic attributes :

18:

Saturation : Saturated
 Number of Carbon Atoms : less than 7

42:

Saturation : Unsaturated

Element Count :

Node 18: Limited
 C,C1-5

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:46:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1195 TO ITERATE

100.0% PROCESSED 1195 ITERATIONS 4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 21827 TO 25973

PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 18:46:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 24300 TO ITERATE

100.0% PROCESSED 24300 ITERATIONS 64 ANSWERS

SEARCH TIME: 00.00.01

L3 64 SEA SSS FUL L1

=> => s l3

L4 7 L3

=> d l4 1-7 bib,ab,hitstr

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:526686 CAPLUS

DN 148:495977

TI Preparation of (oxopyridopyrimidinyl)piperidinylacetamides as lipoprotein associated phospholipase A2 (Lp-PLA2) inhibitors for treating atherosclerosis and other inflammatory diseases

IN Leach, Colin Andrew

PA USA

SO U.S. Pat. Appl. Publ., 25pp., Cont.-in-part of U.S. Ser. No. 626,875.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

common inventor

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080103156	A1	20080501	US 2007-871178	20071012
	US 20080090851	A1	20080417	US 2007-626875	20070125
	US 20080090852	A1	20080417	US 2007-626879	20070125
PRAI	US 2006-829327P	P	20061013		
	US 2007-626875	A2	20070125		
	US 2007-626879	A2	20070125		

OS MARPAT 148:495977

AB Title comps., e.g. I (R1 = CF3, CF3O; R2, R3 = H, F; R4 = ester, amide residue) and their salts were prepared via multistep synthesis and tested for their Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitory activity. Thus, I (R1 = CF3; R2 = F; R3 = H; R4 = MeO2C) was prepared via coupling of [2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetic acid (preparation given) with Me 2-methyl-2-[4-[[[4'-(trifluoromethyl)-4-biphenyl]methyl]amino]-1-piperidinyl]propanoate (preparation given) using diisopropylethylamine and HATU in DMF. I were found to inhibit Lp-PLA2 with IC50 values in the range 0.1 to 10 nM. These comps. or their salts are useful for preventing or treating atherosclerosis, diabetes, rheumatoid arthritis, stroke, myocardial infarction, reperfusion injury, or acute and chronic inflammation.

IT 1018816-11-9P 1018816-13-1P 1018816-15-3P
 1018816-17-5P 1018816-19-7P 1018816-21-1P
 1018816-23-3P 1018816-25-5P 1018816-27-7P
 1018816-29-9P 1018816-31-3P 1018816-33-5P
 1018816-34-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of (oxopyridopyrimidinyl)piperidinylacetamides as Lp-PLA2 inhibitors for treating atherosclerosis and other inflammatory diseases)


RN 1018816-11-9 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)-1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-13-1 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-15-3 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-17-5 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-19-7 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-21-1 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methylamino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-23-3 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-25-5 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methylamino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-27-7 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-29-9 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-31-3 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1018816-33-5 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 1018816-12-0P 1018816-14-2P 1018816-16-4P
1018816-18-6P 1018816-20-0P 1018816-22-2P
1018816-24-4P 1018816-26-6P 1018816-28-8P

1018816-30-2P 1018816-32-4P 1021494-20-1P

1021494-21-2P 1021494-22-3P 1021494-23-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of (oxopyridopyrimidinyl)piperidinylacetamides as Lp-PLA2
inhibitors for treating atherosclerosis and other inflammatory
diseases)

RN 1018816-12-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-11-9

CMF C41 H40 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-14-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-13-1

CMF C42 H42 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-16-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-15-3

CMF C42 H42 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-18-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-17-5

CMF C43 H44 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 1018816-20-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1018816-19-7
 CMF C43 H44 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-22-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-21-1

CMF C41 H40 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-24-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-23-3

CMF C42 H42 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-26-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-25-5

CMF C42 H42 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 1018816-28-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1018816-27-7
 CMF C43 H44 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-30-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-29-9

CMF C43 H44 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1018816-32-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-31-3

CMF C41 H40 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1021494-20-1 CAPLUS

CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 1021494-21-2 CAPLUS
 CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-[1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl]-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)1,1'-biphenyl]-4-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 1021494-20-1
 CMF C44 H45 F5 N6 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 1021494-22-3 CAPLUS

CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-[1,1-dimethyl-2-(methylamino)-2-oxoethyl]-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1021494-23-4 CAPLUS


CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-[1,1-dimethyl-2-(methylamino)-2-oxoethyl]-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 1021494-22-3

CME C41 H41 F5 N6 O3

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:475467 CAPLUS
 DN 148:449657
 TI Preparation of oxypyrido[2,3-d]pyrimidines as Lp-PLA2 inhibitors for
 treating atherosclerosis or other inflammatory diseases
 IN Leach, Colin Andrew
 PA USA
 SO U.S. Pat. Appl. Publ., 19pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2


common inventor

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080090852	A1	20080417	US 2007-626879	20070125
	WO 2008048867	A2	20080424	WO 2007-US81166	20070102
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080103156 A1 20080501 US 2007-871178 20071012 FRAI US 2006-829327P P 20061013 US 2007-626875 A 20070125 US 2007-626879 A 20070125 OS MARPAT 148:449657 AB Comps. of formula I (wherein R1 is (un)substituted aryl group; R2 is C1-6 alkyl, C1-6 alkoxy, etc.; Y is C2-4alkyl; n is 0-5; R3 is C1-4 alkyl; R4 is C1-4 alkyl; or R3 and R4 are combined to form a ring; R5 is C1-10 alkyl, C2-10 alkenyl, etc.) or pharmaceutically acceptable salts thereof are claimed. These comps. have Lp-PLA2 (lipoprotein associated phospholipase A2) inhibitory activity with IC50 values in the range of 0.1-10 nM and are useful for treating atherosclerosis and other inflammatory diseases. Synthetic procedures for preparing I are exemplified. Example compound II was prepared by reacting [2-[2-(2,3-difluorophenyl)ethyl]-4-oxypyrido[2,3-d]pyrimidin-1(4H)-yl]acetic acid (preparation given) and Me 2-methyl-2-[4-[[[4'-(trifluoromethyl)-4-biphenyl]methyl]amino]-1-piperidinyl]propanoate (preparation given). IT 1018816-11-9P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of oxypyrido[2,3-d]pyrimidines as Lp-PLA2 inhibitors for treating atherosclerosis or other inflammatory diseases) RN 1018816-11-9 CAPLUS CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxypyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][4'-(trifluoromethyl)][1,1'-biphenyl]-4-yl]methyl]amino]- α , α -dimethyl-, methyl ester (CA INDEX NAME)				

PAGE 1-A



PAGE 2-A



IT 1018816-12-0P 1018816-13-1P 1018816-14-2P
 1018816-15-3P 1018816-16-4P 1018816-17-5P
 1018816-18-6P 1018816-19-7P 1018816-20-0P
 1018816-21-1P 1018816-22-2P 1018816-23-3P
 1018816-24-4P 1018816-25-5P 1018816-26-6P
 1018816-27-7P 1018816-28-8P 1018816-29-9P
 1018816-30-2P 1018816-31-3P 1018816-32-4P
 1018816-34-6P 1018816-35-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of oxopyrido[2,3-d]pyrimidines as Lp-PLA2
 inhibitors for treating atherosclerosis or other inflammatory diseases)


RN 1018816-12-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1018816-11-9
 CMF C41 H40 F5 N5 O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 87-69-4
 CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-13-1 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-14-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-13-1

CMF C42 H42 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-15-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-16-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-15-3

CMF C42 H42 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-17-5 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-18-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-17-5

CMF C43 H44 F5 N5 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.

CM 1


CRN 1018816-19-7

CMF C43 H44 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-21-1 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-22-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-21-1

CMF C41 H40 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-23-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-24-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-23-3

CMF C42 H42 F5 N5 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.

CM 1


CRN 1018816-25-5

CMF C42 H42 F5 N5 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-27-7 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-28-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-27-7

CMF C43 H44 F5 N5 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.




RN 1018816-29-9 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1-methylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1018816-30-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1018816-29-9

CMF C43 H44 F5 N5 O5

PAGE 1-A



PAGE 2-A



CM 2

CRN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.

CM 1


CRN 1018816-31-3

CMF	C41	H40	F5	N5	O5
-----	-----	-----	----	----	----

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF	C4	H6	O6
-----	----	----	----

Absolute stereochemistry.




RN 1018816-34-6 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 1018816-33-5

CMF C40 H38 F5 N5 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 1018816-35-7 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A





PAGE 2-A

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:474667 CAPLUS
 DN 148:456615
 TI Bicyclic heteroaromatic compounds, quinazolines and naphthyridines, for
 treating atherosclerosis or other inflammatory diseases
 IN Leach, Colin Andrew
 PA USA
 SO U.S. Pat. Appl. Publ., 15pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

common inventor


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080090853	A1	20080417	US 2007-626882	20070125
	WO 2008048866	A2	20080424	WO 2007-US81165	20070102
	W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-829328P	P	20061013		
	US 2007-626882	A	20070125		
OS	MARPAT 148:456615				
AB	A compound of formula (I; R1 = aryl, unsubstituted or substituted by 1, 2, 3 or 4 substituents consisting of C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, aryl C1-C6 alkoxy, hydroxy, halo, CN, COR6, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, halo C1-C4 alkyl, halo C1-C4 alkoxy; W, X = CH or N; Y = C2-C4 alkyl, R2 = H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, aryl C1-C6 alkoxy, hydroxy, halo, CN, COR6, carboxy, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, mono to perfluoro-C1-C6 alkyl, or mono to perfluoro-C1-C6 alkoxy.; n = 0-5; R3, R4 = C1-C4 alkyl; R5 = H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, halo C1-C4 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C4 alkyl, C5-C8 cycloalkenyl, C5-C8 cycloalkenyl C1-C4 alkyl, 3-8-membered heterocycloalkyl, C1-C4 alkyl, C6-C14 aryl, C6-C14 aryl C1-C10 alkyl, heteroaryl, or heteroaryl C1-C10 alkyl, C1-C6 alkylthio, aryl C1-C6 alkoxy, hydroxy, halo, CN, NR8R9, or halo C1-C4 alkoxy; R6, R7 = hydrogen or C1-C10 alkyl; R8, R9 = hydrogen or C1-C10 alkyl), or a pharmaceutically acceptable salt thereof. These compds. are useful for treating atherosclerosis or other inflammatory diseases. Thus, the synthesized compds. were tested for lipoprotein associated phospholipase A2 inhibition activity and were found to have IC50 values in the range 0.1 to 10 nM.				
IT	1019657-99-8P	1019658-01-5P	1019658-02-6P		
	1019658-03-7P	1019658-04-8P	1019658-05-9P		
	1019658-08-2P	1019658-09-3P	1019658-10-6P		
	1019658-12-8P	1019658-16-2P	1019658-20-8P		
	1019658-23-1P	1019658-25-3P	1019658-27-5P		
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

(bicyclic heteroarom. compds., quinazolines and naphthyridines, for treating atherosclerosis or other inflammatory diseases)


RN 1019657-99-8 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazoliny]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1019658-01-5 CAPLUS

CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazoliny]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1019658-03-7 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1019658-04-8 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl][[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1019658-05-9 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,4-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1019658-08-2 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 1019658-09-3 CAPLUS
 CN 1-Piperidineacetic acid, 4-[[2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl][[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]- α,α -dimethyl-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)


CM 1

CRN 1019658-08-2
 CMF C41 H39 F5 N4 O4

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1019658-10-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1019658-08-2

CMF C41 H39 F5 N4 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 1019658-12-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1019657-99-8
 CMF C42 H41 F5 N4 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1019658-16-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1019658-01-5

CMF C43 H43 F5 N4 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1019658-20-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1019658-02-6

CMF C43 H43 F5 N4 O5

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1019658-23-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

CM 1


CRN 1019658-03-7

CMF C42 H41 F5 N4 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 1019658-25-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1019658-05-9
 CMF C43 H43 F5 N4 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 1019658-27-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED


CM 1

CRN 1019658-04-8

CMF C43 H43 F5 N4 O5

PAGE 1-A






CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:836853 CAPLUS
 DN 139:337978
 TI Preparation of N-substituted pyridinone and pyrimidinone derivatives for
 use as Lp-PLA2 inhibitors in the treatment of atherosclerosis
 IN Leach, Colin Andrew; Smith, Stephen Allan
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Applicant's

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086400	A1	20031023	WO 2003-GB1544	20030410
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003217074	A1	20031027	AU 2003-217074	20030410
	EP 1492533	A1	20050105	EP 2003-712462	20030410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 200553757	T	20051110	JP 2003-583419	20030410
	US 20050245552	A1	20051103	US 2005-510467	20050525
PRAI	GB 2002-8279	A	20020410		
	WO 2003-GB1544	W	20030410		

OS MARPAT 139:337978

AB The title compds. [I; R1 = (un)substituted aryl; R2 = halo, alkyl, alkoxy, etc.; R3 = H, halo, alkyl, hydroxyalkyl; R2 and R3 together with the pyridone or pyrimidinone ring carbons to which they are attached form (un)substituted fused 5-6 membered carbocyclic ring, fused benzo or heteroaryl ring; R4 = alkyl substituted by 5-7 membered saturated heterocyclyl comprising N and optionally O or S; R5 = (un)substituted (hetero)aryl; R6 = (un)substituted (hetero)aryl; X = CH, N; Y = alkylene, CH₂CH, (CH₂)_nS; n = 1-3] that are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis, were prepared Thus, amidation of 2-[2-((2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl)acetic acid with N-(1-thiazol-2-ylmethylpiperidin-4-yl)-4'-trifluoromethylbiphen-4-ylmethylaniline (prepn. given) afforded the quinolinone II. The exemplified compds. I showed IC50 values in the range <0.1 to 100 nM against Lp-PLA2.

IT 615577-22-5P 615577-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyridinone and pyrimidinone derivs. for use as Lp-PLA2 inhibitors in the treatment of atherosclerosis)

RN 615577-22-5 CAPLUS


CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-N-[4'-

(trifluoromethyl) [1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 615577-23-6 CAPLUS
 CN 1(4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-N-[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:154252 CAPLUS

DN 138:205073

TI Preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones with Lp-PLA2 inhibitory activity for the treatment of atherosclerosis

IN Elliott, Richard Leonard, Leach, Colin Andrew, Smith, Stephen Allan

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

common inventor

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015786	A1	20030227	WO 2002-EP9068	20020813
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002336967	A1	20030303	AU 2002-336967	20020813
PRAI	GB 2001-19793	A	20010814		
	WO 2002-EP9068	W	20020813		
OS	MARPAT 138:205073				

AB The title compds. [I; R1, R2 = (un)substituted (hetero)aryl; R3 = Het(alkyl) (wherein Het = (un)substituted 5-7 membered heterocyclyl, bonded directly through a ring carbon atom, comprising N atom and optionally O or S); R4 = (un)substituted (hetero)aryl; R5 = (un)substituted aryl; n = 1-4; X = O, S; Z = CR13R14 (R13, R14 = H, alkyl; or R13 and R14 together with the intervening carbon atom form cycloalkyl)] which are inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2) and are of use in therapy, in particular for treating atherosclerosis, were prepared. Thus, amidation of N-[1-(2-methoxyethyl)piperidin-4-yl]-4-(4-trifluoromethylphenyl)benzylamine with 1-(carboxymethyl)-2-(2,3-difluorobenzylthio)-5-[(1-methylpyrazol-4-yl)methyl]pyrimidin-4-one (prepn. given) in the presence of HATU and (iso-Pr)2NH in DMF afforded II. The compds. I described in the examples were tested for Lp-PLA2 inhibition and demonstrated IC50 values in the range 1 to 0.01 nM.

IT 500132-05-8P 500132-06-9P 500132-08-1P


500132-09-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,5-substituted 1-(aminocarbonylalkyl)-pyrimidin-4-ones with Lp-PLA2 inhibitory activity for the treatment of atherosclerosis)

RN 500132-05-8 CAPLUS


CN 1(4H)-Pyrimidineacetamide, 2-[[2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)



RN 500132-06-9 CAPLUS
 CN 1-(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 500132-05-8
 CMF C40 H41 F5 N6 O3 S




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 500132-08-1 CAPLUS


CN 1-(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 500132-09-2 CAPLUS
 CN 1(4H)-Pyrimidineacetamide, 2-[[[(2,3-difluorophenyl)methyl]thio]-N-(1-ethyl-4-piperidinyl)-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (CA INDEX NAME)

CM 1

CRN 500132-08-1
 CMF C39 H39 F5 N6 O2 S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2002:293633 CAPLUS
 DN 136:325562
 TI Preparation of pyrimidinones as lipoprotein associated phospholipase A2
 inhibitors for the treatment of atherosclerosis.
 IN Elliott, Richard Leonard; Hickey, Deirdre Mary Bernadette; Ife, Robert
 John; Leach, Colin Andrew; Pinto, Ivan Leo; Smith, Stephen Allen
 PA Smithkline Beecham P.L.C., UK
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

common inventor

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030911	A1	20020418	WO 2001-EP11562	20011005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2459746	A1	20020418	CA 2001-2459746	20011005
	AU 2002023599	A	20020422	AU 2002-23599	20011005
	EP 1337517	A1	20030827	EP 2001-986682	20011005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511473	T	20040415	JP 2002-534297	20011005
	US 20040058941	A1	20040325	US 2003-398977	20030902
	US 7169924	B2	20070130	no ODP	
	US 20060241126	A1	20061026	US 2006-456129	20060707
PRAI	GB 2000-24807	A	20001010	ODP	
	WO 2001-EP11562	W	20011005		
	US 2003-398977	A3	20030902		

OS MARPAT 136:325562
 AB Title compds. [I; R1 = (substituted) aryl; R2 = halo, alkyl, alkoxy, hydroxyalkyl, alkylthio, aminoalkyl, alkylcarboxy, alkylcarbonylaminoalkyl, etc.; R3 = H, halo, alkyl, hydroxyalkyl; R2R3 = atoms to form a (substituted) ring; R4 = H, (substituted) alkyl, heterocyclyl(alkyl); R5, R6 = (substituted) aryl, heteroaryl; X = (substituted) alkylene, CH:CH], were prepared. Thus, N-[2-(diethylamino)ethyl]-4-(4-(trifluoromethylphenyl)benzylamine (preparation given), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, 1-hydroxybenzotriazole hydrate, and 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-4H-quinazolin-1-yl]acetic acid (preparation given) were stirred overnight in CH2Cl2 to give 88% N-(2-diethylaminoethyl)-2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-4H-quinazolin-1-yl-N-(4'-trifluoromethylbiphen-4-ylmethyl)acetamide bitartrate. Tested I inhibited Ip-PLA2 with IC50 values in the range of <0.1 nM to 200 nM.
 IT 412960-89-5P 412960-90-8P 412961-14-9P
 412961-15-0P 412961-17-2P 412961-20-7P
 412961-21-8P 412961-23-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of pyrimidinones as lipoprotein associated phospholipase A2 inhibitors for the treatment of atherosclerosis)


RN 412960-89-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-methyl-4-piperidinyl)-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 412960-90-8 CAPLUS

CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 412961-14-9 CAPLUS
 CN 1(4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-methyl-4-piperidinyl)-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 412961-15-0 CAPLUS
 CN 1(4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-methyl-4-piperidiny)-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 412961-14-9
 CMF C38 H35 F5 N4 O2

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 412961-17-2 CAPLUS


CN 1 (4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-ethyl-4-piperidiny)-4-oxo-N-[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 412961-16-1

CMF C37 H35 F5 N4 O2 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 412961-20-7 CAPLUS


CN 1(4H)-Quinazolineacetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-ethyl-4-piperidinyl)-4-oxo-N-[[4-[5-(trifluoromethyl)-2-thienyl]phenyl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 412961-19-4

CMF C37 H35 F5 N4 O2 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 412961-21-8 CAPLUS


CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-(1-methyl-4-piperidiny)-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 412960-89-5

CMF C37 H34 F5 N5 O2

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 412961-23-0 CAPLUS


CN Pyrido[2,3-d]pyrimidine-1(4H)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-N-[1-(2-methoxyethyl)-4-piperidiny]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 412960-90-8

CMF C39 H38 F5 N5 O3

PAGE 1-A



PAGE 2-A




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/510,467


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:617985 CAPLUS
 DN 135:195570
 TI Preparation of pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
 IN Hickey, Deirdre Mary Bernadette; Iffe, Robert John; Leach, Colin Andrew;
 Pinto, Ivan Leo; Smith, Stephen Allan; Stanway, Steven James
 PA Smithkline Beecham P.L.C., UK
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060805	A1	20010823	WO 2001-EP1515	20010213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2400554	A1	20010823	CA 2001-2400554	20010213
	AU 2001035466	A	20010827	AU 2001-35466	20010213
	EP 1263740	A1	20021211	EP 2001-907522	20010213
	EP 1263740	B1	20060719		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008396	A	20030311	BR 2001-8396	20010213
	HU 2002004410	A2	20030528	HU 2002-4410	20010213
	HU 2002004410	A3	20030728		
	JP 2003523335	T	20030805	JP 2001-560190	20010213
	JP 4095804	B2	20080604		
	NZ 520752	A	20040326	NZ 2001-520752	20010213
	AU 2001235466	B2	20040422	AU 2001-235466	20010213
	RU 2235722	C2	20040910	RU 2002-124611	20010213
	EP 1686119	A1	20060802	EP 2006-75890	20010213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
	AT 333446	T	20060815	AT 2001-907522	20010213
	ES 2267714	T3	20070316	ES 2001-907522	20010213
	US 20020103213	A1	20020801	US 2001-782930	20010214
	TW 550259	B	20030901	TW 2001-90103332	20010215
	IN 2002MN01086	A	20050304	IN 2002-MN1086	20020812
	NO 2002003828	A	20020930	NO 2002-3828	20020813
	NO 324691	B1	20071203		
	ZA 2002006528	A	20030313	ZA 2002-6528	20020815
	MX 2002PA08062	A	20021129	MX 2002-PA8062	20020816
	KR 781425	B1	20071203	KR 2002-710662	20020816
	BG 107034	A	20030430	BG 2002-107034	20020826
	US 6649619	B1	20031118	US 2003-357238	20030203
	HK 1053466	A1	20070209	HK 2003-104052	20030609
	US 20040097525	A1	20040520	US 2003-694561	20031027
	US 7153861	B2	20061226		
	US 20070155762	A1	20070705	US 2006-561035	20061117

	US 20070123549	A1	20070531	US 2006-561926	20061121
PRAI	GB 2000-3636	A	20000216		
	GB 2001-1437	A	20010119		
	EP 2001-907522	A3	20010213		
	WO 2001-EP1515	W	20010213		
	US 2001-782930	B1	20010214		
	US 2003-357238	A3	20030203		
	US 2003-694561	A3	20031027		
OS	MARPAT 135:195570				
AB	<p>The title compds. [I; Ra = H, halo, alkyl, etc.; Rb = H, halo, alkyl, etc.; Ra and Rb together = (CH₂)_n (n = 3-4) or Ra and Rb together with the pyrimidine ring carbon atoms to which they are attached form (un)substituted fused benzo or heteroaryl ring; Rc = H, alkyl; R2 = (un)substituted (hetero)aryl; R3 = H, alkyl, halo, etc.; R4 = (un)substituted (hetero)arylene; R5 = (un)substituted (hetero)aryl; n = 1-4; X = O, S; Y = (CH₂)_pO_q (p = 1-3 and q = 0; p = 2-3 and q = 1); Z = O, a bond] which are inhibitors of the enzyme Lp-PLA₂ useful in treating atherosclerosis, were prepared. Thus, reacting N-[2-(diethylamino)ethyl]-4-(4-trifluoromethylphenyl)benzylamine with 1-(carboxymethyl)-2-(4-fluorobenzylthio)-5-ethylpyrimidin-4-one in the presence of HATU and (iso-Pr)₂NEt in CH₂Cl₂ afforded the pyrimidinone II. The compds. I described in Examples were tested for Lp-PLA₂ inhibition and showed IC₅₀ values in the range <0.1 nM to 10 μM.</p>				
IT	356057-98-2P 356058-05-4P 356058-06-5P 356058-07-6P				
	<p>RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidine-4-one derivs. as LDL-PLA₂ inhibitors)</p>				
RN	356057-98-2	CAPLUS			
CN	<p>1H-Cyclopentapyrimidine-1-acetamide, N-(1-ethyl-4-piperidinyl)-2-[[[4-(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)</p>				

PAGE 1-A




PAGE 2-A




RN 356058-05-4 CAPLUS
 CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[[(4-fluorophenyl)methyl]thio]-
 4,5,6,7-tetrahydro-N-(1-methyl-4-piperidiny)-4-oxo-N-[[4'-
 (trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 356058-06-5 CAPLUS
 CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[[(4-fluorophenyl)methyl]thio]-
 4,5,6,7-tetrahydro-N-[1-(1-methylethyl)-4-piperidinyl]-4-oxo-N-[[4'-
 (trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 356058-07-6 CAPLUS
 CN 1H-Cyclopentapyrimidine-1-acetamide, 2-[[[(4-fluorophenyl)methyl]thio]-
 4,5,6,7-tetrahydro-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-[[4'-(
 (trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/510,467

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

38.63

217.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.60

-5.60

STN INTERNATIONAL LOGOFF AT 18:47:39 ON 02 JUL 2008